B
IOVA icon

Bellecapital’s Iovance Biotherapeutics IOVA Stock Holding History

Bellecapital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,928
Closed -$228K – 190
2020
Q3 		$228K Buy
+6,928
New +$212K 0.1% 145
2020
Q2 		– Sell
-6,928
Closed -$207K – 169
2020
Q1 		$207K Buy
+6,928
New +$184K 0.13% 138

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bellecapital's IOVA Position: Q4 2020 in Review

Bellecapital sold out of Iovance Biotherapeutics (IOVA) in Q4 2020, closing a stake of 6,928 shares — an estimated $228K sold.

Bellecapital first reported a position in IOVA in Q1 2020 and held it in 2 quarters. The position peaked at $228K in Q3 2020. 269 funds tracked by Wall St. Rank hold IOVA as of Q4 2020.

  • Bellecapital reported no remaining Iovance Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Bellecapital sold 6,928 Iovance Biotherapeutics shares in Q4 2020, an estimated $228K.
  • Bellecapital first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 2 quarters.
  • Bellecapital's Iovance Biotherapeutics position peaked at $228K in Q3 2020.
  • 269 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2020.

Based on Bellecapital's 13F filing for Q4 2020, filed 14 Jan 2021.